Moderna, Pfizer and COVID-19

Pfizer convinces US Patent Office to cancel two Moderna COVID-19 vaccine patents
Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U.S. Patent Office tribunal that two patents Moderna accused them of infringing were invalid.
US Patent Board invalidates Moderna vaccine IP
The US Patent Trial and Appeal Board handed a massive victory to Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) on Wednesday, as it invalidated two of Moderna (Nasdaq: MRNA) patents covering its Spikevax COVID-19 vaccine,
Pfizer and BioNTech violated COVID-19 vaccine patent held by Moderna, German court rules
The court said Pfizer and BioNTech would have to provide information on earnings derived from the use of the patent and that they owe Moderna appropriate compensation
German court rules Pfizer, BioNTech violated Moderna's COVID-19 vaccine patent
A German court on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna .
Pfizer and BioNTech COVID vaccine broke patent — German court
FRANKFURT - A German court found Wednesday that American pharmaceutical giant Pfizer and German firm BioNTech violated a patent to make their COVID-19 vaccine.Siding with Moderna, an American pharmaceutical firm that brought the case,
Moderna wins patent lawsuit against BioNTech/Pfizer in German court
A German court ruled on Wednesday that BioNTech and Pfizer violated a Covid-19 patent held by rival Moderna. US-based Moderna had asserted claims for information and damages for infringement of its patent rights in the development of the Covid-19 vaccine.
Zacks Investment Research on MSN2d
Here's Why Moderna Stock Soared 16% on Wednesday
Shares of Moderna MRNA rose nearly 16% yesterday after a couple of SEC filings showed that two board members bought shares on ...
Moderna: Patent Litigation Win Masks Underperformance, Unlikely To Pay Out
Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...
Why Moderna (MRNA) Stock Is Rallying Today
Moderna (MRNA) stock is climbing 8% after the drug maker won a key court case and its CEO bought shares on the open market.
Zacks.com on MSN12d
Vaccine Stocks Rise as Chinese Scientists Discover a New Coronavirus
Stocks of MRNA, PFE, NVAX and BNTX rose in anticipation that a new virus in China could trigger another pandemic.
CDC plans study into potential vaccines, autism connections, Reuters reports
The U.S. CDC plans to embark on a large study into potential connections between vaccines and autism, despite extensive scientific research ...
Why Moderna, Celanese, and HII Rallied
After finding support at $30, Moderna (MRNA) added nearly $5.00 to close at $35.21. The firm participated in TD Cowen’s ...